Phase I Study of mPEG-R-Crisantaspase Given IV

A Dose Escalation Phase I Study of Asparec®(mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies

This study is an open label, multicenter study with a dose escalation of Asparec® administered once every two to four weeks for two administrations. The primary objective of this study is to determine the Maximum Tolerated Dose following one single dose of Asparec when administered in a population of patients with relapsed or refractory hematological malignancies, as measured by Dose Limiting toxicities. There are secondary objectives which are to evaluate the safety of Asparec and to determine the PK profile as assessed by measurement of plasma L-asparaginase enzymatic activity following single and repeated doses of Asparec. Patients response rate will be evaluated and Anti-Asparec antibodies will be measured.

Study Overview

• Status: Completed
• Conditions: Hematologic Malignancies
• Intervention / Treatment: Biological: mPEG-r-crisantaspase

Detailed Description

Planned sample size: Up to 36 evaluable subjects will be enrolled in the study: a maximum of 30 subjects for the dose escalation phase and up to a maximum of 12 patients in the expansion phase.

Inclusion criteria consists of:

Patients with any relapsed or refractory hematological malignancy, for which standard curative or life prolonging treatment does not exist, or is no longer effective or tolerable.

For the following hematological malignancies, patients must have received at least: Low rade NHL: 3 prior lines of therapy, ALL, aggressive NHL and other hematological malignancies: 2 prior lines of therapy, Aged 18 to 50 years and ECOG performance status of 1, 1 or 2.

All patients will be treated with Asparec once every two to four weeks for two IV administrations infused in 60 minutes. Patients without Disease Progression may receive additional administrations, each administration starting at least 14 days but no later than 28 days after the previous Asparec administration.

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Créteil, France, 94010
    • Hopital Henri Mondor
  • Nantes, France
    • Hôpitaux du CHU de Nantes
  • Pierre-Bénite, France, 69495
    • Hospices Civils de Lyon
  • Toulouse, France, 31052
    • Institut Claudius Regaud
  • Cedex
    • Rouen, Cedex, France, 76038
      • Centre Henri Becquerel

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with any relapsed or refractory hematological malignancy, for which standard curative or life prolonging treatment does not exist, or is no longer effective or tolerable.

• For the following hematological malignancies, patients must have received at least:

  • Low grade NHL:

    • 3 prior lines of therapy and ALL,

  • aggressive NHL and other hematological malignancies:

    • 2 prior lines of therapy.
• Ages 18 to 50 years and
• ECOG performance status of 0, 1 or 2,
• ability to understand and to sign a written informed consent and
• have a life expectancy of greater than or equal to 90 days

Exclusion Criteria:

• Any active CNS disease,
• previous greater than or equal to grade 3 allergic reaction to Erwinase,
• patients who have experienced a greater than or equal to grade 3 allergic reaction to E. coli L-asparaginase and who have never received E. chrysanthemi L-asparaginase after the occurrence of this reaction,
• WBC count greater than 20 Gica/L, any of the following laboratory abnormalities if not due to hematologic malignancy (calculated creatinine clearance less than 50 mL/min,
• serum SGOT/AST or SGPT?ALT greater than 2.5 x upper limit of normal,
• serum total bilirubin greater than 2.0 mg/dL, except in the case of hemolytic anemia.
• Patients cannot have a history of greater than or equal to grade 2 pancreatitis,
• any history of allogeneic transplant,
• receiving steroid therapy with a dose greater than 20 mg/day,
• known HIV positive serology,
• active hepatitis B or C,
• any serious active disease or comorbid medical condition or psychiatric illness that would prevent the subject from signing the informed consent.
• Pregnant or lactating females or women of child bearing potential not willing to use an adequate method of birth control for the duration of the study are not eligible.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intravenous Erwinia	Biological: mPEG-r-crisantaspase; IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%; Other Names: Asparec

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose	To determine the Maximum Tolerated Dose following one single dose of mPEG-r-Crisantaspase when administered in a population of patients with relapsed or refractory hematological malignancies, as measured by Dose Limiting Toxicities.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Asparaginase Activity in serum	To determine the pharmacokinetic profile as assessed by measurement of serum L-asparaginase enzymatic activity following single and double mPEG-r-chrisantaspace doses.	6 months

Collaborators and Investigators

• Sponsor: Jazz Pharmaceuticals
• Collaborators: The Lymphoma Academic Research Organisation; EUSA SAS
• Investigators: Principal Investigator: Pr Gilles Salles, MD, Centre Hospitalier Lyon Sud -Chemin du Grand Revoyet; Study Director: Xavier Thomas, MD, Centre Hospitalier Lyon Sud - Chemin du Grand Revoyet

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (Actual): February 1, 2015
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: March 8, 2012
• First Submitted That Met QC Criteria: March 9, 2012
• First Posted (Estimate): March 12, 2012

Study Record Updates

• Last Update Posted (Estimate): May 7, 2015
• Last Update Submitted That Met QC Criteria: May 5, 2015
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Keywords: Lymphoma; Leukemia; C240588.448; C115.378.400
• Additional Relevant MeSH Terms: Neoplasms by Site; Hematologic Diseases; Neoplasms; Hematologic Neoplasms
• Other Study ID Numbers: AZPO2-CLT-001; 2011-000295-34 (EudraCT Number)